RESEARCH ARTICLE

Hypoxia-inducible Factor 1 Alpha (HIF-1α) as a Prognostic Indicator in Patients with Gastric Tumors: A Meta-analysis

Zhi-Gang Zhang1,2, Qiu-Ning Zhang2,3, Xiao-Hu Wang1,2,3, Jin-Hui Tian1,2

Abstract

Background and Objective: Though researched for years, the prognostic role of hypoxia-inducible factor 1 alpha (HIF-1α) ingastric cancer is still controversial. We thus undertook a systematic review to assess the relationship. Method: A systematically literature search of Pubmed, Embase, Web of Science, China Biological Medicine Disc and Cochrane Library was undertaken in February 2013, and the reference lists of articles were retrieved. Results: 12 trials (1,555 participants) were included to assess the association between HIF-1α expression and survival. Summary hazard ratios (HRs) were calculated. HIF-1α expression was significantly correlated with poor overall survival of gastric cancer patients (HR=1.34, 95%CI: 1.13-1.58; \(P=0.0009\)), but not with poor disease free survival of gastric cancer patients (HR=1.67, 95%CI: 0.99-2.82; \(P=0.06\)). Conclusion: HIF-1α was associated with poor OS, but not DFS, especially for Asian patients. But studies evaluating relationships of HIF-1α with OS and DFS in non-Asian gastric cancer patients appear needed.

Keywords: Stomach neoplasm - Hypoxia-inducible factor - survival - meta-analysis

Introduction

Although its declining incidence, gastric tumor still accounted for 8% of the total new cancer cases and 10% of total deaths caused by cancer worldwide (Bertuccio et al., 2009; Jemal et al., 2011). The highest incidence rates were high in Eastern Asia, Eastern Europe, and South America while twice as high in males as in females. Despite improvement in surgical techniques and oncology treatments, the prognosis of gastric cancers was still poor. New treatment methods are still needed and new therapy targets may help.

HIF was recognized to be the master regulatory protein in the response of cells to change oxygen levels (Semenza., 2003). HIF family composed of bHLH-PAS proteins including an \(O_{2}\)-labile alpha subunit (HIF-1α, HIF-2α, or HIF-3α) and a stable beta subunit (HIF-1β), which together bind hypoxia responsive elements (HREs). HIF-1α accounts for an important effect on tumor growth and progression which is degraded in normoxia, but stabilized in hypoxia. HIF-1α expression in a variety of human cancers tissue was first observed by Zhong, et al. (Zhong et al., 1999). Then subsequent studies with greater numbers of patients had observed a negative correlation between HIF-1α expression and prognosis. And the targeted inhibition of HIF-1α has been shown to inhibit the growth of gastric tumors in animals (Yeo et al., 2003; Stoeltzing et al., 2004). But there were still conflicting results in several tumor sub-sites, including cervical, lung and ovarian cancer. The prognostic role of HIF-1α in gastric tumor had been searched in many trials particular in East Asia. Most have shown expression of HIF-1α was associated with a poor prognosis; however, others didn’t or only showed a trend without statistically significance. Aiming to evaluate the prognostic role of HIF-1α expression in gastric tumor, we undertook a systematic review according to the Cochrane Handbook 5.1.

Materials and Methods

Search strategy

Systematic literature searches in Cochrane Library, PubMed, EMBASE, Web of Science, and China Biological Medicine Disc were conducted to identify available clinical studies. All search queries were updated until February 2013. The keywords were (‘Hypoxia-inducible factor 1’ OR HIF 1) AND (‘Gastric’ OR ‘stomach’ OR ‘Gastro*’) AND (‘adenocarcinoma’ OR ‘carcinoma’ OR ‘tumor’ OR ‘cancer’ OR ‘Neoplasm’ OR ‘malignan*’). MeSH terms as well as free text words were used. Pre-retrievals were performed to adjust the search queries in the individual database. In addition, reference lists were traced to complement search queries.

Selection criteria

Clinical studies identified by the searches were scrutinized by two independent observers (Zhang ZG and Zhang QN). Publications were included in pooled analyses if they met all of the following criteria: 1). The patients must be gastric cancer patients.

1Evidence Based Medicine Center of Lanzhou University, 2The First Clinical Medical College of Lanzhou University, 3Department of Radiation Oncology, Gansu Provincial Tumor Hospital, Lanzhou, China *For correspondence: xhwanggs@126.com
Table 1. The General Characteristics of Included Studies

<table>
<thead>
<tr>
<th>Author and year of publication</th>
<th>Study location</th>
<th>No of tissue specimens</th>
<th>criteria of HIF-1α expression</th>
<th>Outcomes</th>
<th>follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isobe T 2012</td>
<td>Japan</td>
<td>128</td>
<td>Positive if TNS ≥ 5%</td>
<td>OS, DFS</td>
<td>44.9 (0-60)</td>
</tr>
<tr>
<td>Qiu MZ 2011</td>
<td>China</td>
<td>188</td>
<td>Positive if HIF-1α at both the cancer central and invasive front intensity (0-no, 1-light, 2-moderate, 3-severe) positive if intensity ≥ 1</td>
<td>OS</td>
<td>60 (3-120)</td>
</tr>
<tr>
<td>Shen CL 2010</td>
<td>China</td>
<td>135</td>
<td></td>
<td>OS</td>
<td>(5-104)</td>
</tr>
<tr>
<td>Nakamura J 2009</td>
<td>Japan</td>
<td>91</td>
<td>Positive if TNS at both the cancer central and invasive front</td>
<td>DFS</td>
<td>22.5 (0.3-99.8)</td>
</tr>
<tr>
<td>Zhou LH 2009</td>
<td>China</td>
<td>62</td>
<td>Positive if TNS ≥ 10%</td>
<td>OS</td>
<td>(1-82)</td>
</tr>
<tr>
<td>Oh SY 2008</td>
<td>Korea</td>
<td>114</td>
<td>Positive if TNS ≥ 10%</td>
<td>DFS</td>
<td>24.5 (14-32)</td>
</tr>
<tr>
<td>Kolev Y 2008</td>
<td>Japan</td>
<td>152</td>
<td>Strong CS ≥ 50% or TNS ≥ 10%</td>
<td>OS, DFS</td>
<td>53 (1-144)</td>
</tr>
<tr>
<td>Griffiths EA 2007</td>
<td>UK</td>
<td>135</td>
<td>positive if TNS ≥ 0%</td>
<td>OS, DFS</td>
<td>48 (13-118)</td>
</tr>
<tr>
<td>Yang ZR 2007</td>
<td>China</td>
<td>135</td>
<td>intensity (0-no, 1-light, 2-moderate, 3-severe) positive if intensity ≥ 1</td>
<td>OS</td>
<td>18 (2-40)</td>
</tr>
<tr>
<td>Urano N 2006</td>
<td>Japan</td>
<td>146</td>
<td>Positive if TNS ≥ 10%</td>
<td>OS</td>
<td>(0-90)</td>
</tr>
<tr>
<td>Sumiyoshi Y 2006</td>
<td>Japan</td>
<td>216</td>
<td>Positive if TNS ≥ 10%</td>
<td>OS</td>
<td>(0-60)</td>
</tr>
<tr>
<td>Takahashi R 2003</td>
<td>Japan</td>
<td>53</td>
<td>Positive if TNS ≥ 10%</td>
<td>OS</td>
<td>81.7±63.2* (12-222)</td>
</tr>
</tbody>
</table>

TNS, Tumour nuclear staining; CS, cytoplasmic staining; CF, clinicopathological features; OS, overall survival; DFS, disease free survival; RFS, relapse free survival *Mean ±SD

2). Studies compared the different outcomes between HIF-1 expression or not.
3). The immunohistochemical staining method and the diagnosis criteria of HIF-1 expression must be reported.
4). If studies involved multiple cancer patients, there must be a subgroup analysis of gastric cancer.
5) Studies must report overall survival (OS) or disease free survival (DFS).

Data extraction
Following data were extracted and cross-checked from all clinical studies by two individual authors (Zhang ZG and Zhang QN). Firstly, General characteristics: first author, year of publication, sample size, study location, assessment of HIF-1α staining. If necessary data were extracted from figures, discrepancies were discussed together for a unanimous decision. If the HR or standard errors (SE) weren’t reported in included studies, we calculate or estimate the HR from available data or Kaplan-Meie curves using the methods reported by Tierney et al. (2007).

Statistical analysis
For primary outcomes, hazard ratio (HR) was used for meta-analyses; pooled analyses by inverse variance method using random-effects models. Heterogeneity between trials was assessed by means of the I² test and Cochran’s Q statistic. All meta-analyses were performed in Review Manager 5.1 and a P-value 0.05 was considered statistically significant.

Results
The search strategies identified 12 eligible clinical studies (Takahashi et al., 2003; Sumiyoshi et al., 2006; Urano et al., 2006; Griffiths et al., 2007; Yang et al., 2007; Kolev et al., 2008; Oh et al., 2008; Zhou et al., 2009; Nakamura et al., 2010; Shen et al., 2010; Qiu et al., 2011; Isobe et al., 2013). PRISMA flowchart was described in Figure 1. Flow Chart

Overall Survival (OS)
Compared with non-expression, HIF-1α expression was associated with significantly worse OS (HR=1.34, 95% CI: 1.13-1.58; P=0.0009) (Takahashi et al., 2003; Sumiyoshi et al., 2006; Urano et al., 2006; Griffiths et al., 2007; Yang et al., 2007; Kolev et al., 2008; Zhou et al., 2009; Shen et al., 2010; Qiu et al., 2011; Isobe et al., 2013) (Figure 2).

DFS
Compared with non-expression, HIF-1α expression was not associated with significantly worse DFS (HR=1.67, 95% CI: 0.99-2.82; P=0.06) (Kolev et al., 2008; 4196 Asian Pacific Journal of Cancer Prevention, Vol 14, 2013
Discussion

**Summary of finding:** Available evidence indicated HIF-1α was associated with worse OS, but not associated with worse DFS. Since expression of HIF-1α was first observed in some tumors types by Zhong et al. (1999), it has emerged as a key regulator of the growth of solid tumors by subsequent studies. Over the past ten years, there was increased evidence suggesting that HIF-1α may be involved in the development and prognosis of gastric tumorigenesis. When uncommonly expressed or low expressed in normal or benign gastric tissue, positive HIF-1α staining was found in pre-malignant gastric tissue such as H. pylori gastritis, intestinal metaplasia, etc (Griffiths et al., 2007). And progressively increased expression has been observed in the pre-malignant and malignant phase of gastric tumors.

Tumorigenesis is a multistep process that requires certain properties include uncontrolled cell division, suppression of senescence, inhibition of apoptosis and induction of angiogenesis (Hanahan et al., 2000). In the process, HIF-1α expression may be influenced by factors other than hypoxia. Vascular endothelial growth factor (VEGF) expression is a key factor in angiogenesis which is essential for growth and metastasis of solid tumors. A recent Meta-analysis had demonstrated that positive expression of tissue VEGF were associated with poor prognosis in resectable gastric cancer (Liu et al., 2012). When tumors grow larger, newly vessels should generate to deliver oxygen because the diffusion distances limitation of oxygen. Tumor vascularity can be assessed by staining the blood vessel endothelia in the tissue and expressed in microvessel density (Vermeulen et al., 1996).

HIF-1α may present as a regulatory protein in the expression of VEGF. There was one study reported the worst prognosis in patients with VEGF (+) and HIF-1α (+) (Isobe et al., 2013). So based on available evidence, HIF-1α could be recognized as an independent prognostic factor in patients with gastric tumors.

**Strength and limitations:** This meta-analysis used rigor meta-analysis methods to evaluate the relationship of HIF-1α with gastric cancer OS and DFS, and included all available study about this topic. However, our meta-analysis still has limitations.

First: Most studies we included were about Asian patients. And few non-Asian studies were found.

Second: Though immunohistochemical assays method of HIF-1α was similar, the positive criterion of HIF-1α was different among studies. Though tumor nuclear staining were conducted in all included studies, the thresholds proportion of tumor nuclear staining to determine positive HIF-1α varied from 0 to 10%. And also there was some different grading standard to identify weak, distinct or strong expression. In two studies (Nakamura et al., 2010; Qiu et al., 2011), TNS at both the cancer central and invasive front was identified as positive.

**Implications:** Available evidence showed that HIF-1α was associated with worse OS, but not associated with worse DFS. However, most studies were from Asian countries, so studies in non-Asian countries should be conducted in the future.

At the same time, the thresholds proportion of tumor nuclear staining to determine positive HIF-1α varied among studies, so in the future, a well recognized standard should be formed worldwide.

In conclusion, HIF-1α was associated with poor OS, but not DFS, especially for Asian patients. But studies that evaluated the relationships of HIF-1α with OS and DFS in non-Asian gastric cancer patients were needed.

**Acknowledgements**

The author(s) declare that they have no competing interests.

**References**


Kolev Y, Uetake H, Takagi Y, Sugihara K (2008). Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-
Zhi-Gang Zhang et al


